These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21804501

  • 1. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome.
    Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M.
    Mymensingh Med J; 2011 Jul; 20(3):397-401. PubMed ID: 21804501
    [Abstract] [Full Text] [Related]

  • 2. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.
    Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK.
    Nutr J; 2016 Feb 27; 15():21. PubMed ID: 26922379
    [Abstract] [Full Text] [Related]

  • 3. Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study.
    Bustos Fernández LM, Man F, Lasa JS.
    Dig Dis; 2023 Feb 27; 41(5):798-809. PubMed ID: 36630947
    [Abstract] [Full Text] [Related]

  • 4. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.
    McFarland LV.
    World J Gastroenterol; 2010 May 14; 16(18):2202-22. PubMed ID: 20458757
    [Abstract] [Full Text] [Related]

  • 5. Irritable Bowel Syndrome: Effects of a Probiotic Combination in Reducing Stress Response and Symptoms Associated With Irritable Bowel Syndrome.
    Ross SM.
    Holist Nurs Pract; 2010 May 14; 38(2):120-122. PubMed ID: 38363971
    [No Abstract] [Full Text] [Related]

  • 6. [Thirty two cases of diarrhea-predominant irritable bowel syndrome treated by ginger-partitioned moxibustion and acupoint application in dog days].
    Gao F.
    Zhongguo Zhen Jiu; 2014 Mar 14; 34(3):218. PubMed ID: 24843956
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis.
    Mansour-Ghanaei F, Dehbashi N, Yazdanparast K, Shafaghi A.
    World J Gastroenterol; 2003 Aug 14; 9(8):1832-3. PubMed ID: 12918131
    [Abstract] [Full Text] [Related]

  • 8. Symptom relief for patients with diarrhoeal irritable bowel syndrome with anxiety and depression.
    Chen P, Wang X, Hou L, Luo Y.
    Asian J Surg; 2024 Jul 14; 47(7):3113-3114. PubMed ID: 38490867
    [No Abstract] [Full Text] [Related]

  • 9. Effectiveness of Saccharomyces boulardii CNCM I-745 in Adult Indian Patients with Diarrhoea: A Real-world, Multicentre, Retrospective, Comparative Study.
    Pal BB, Bandagi RV, Pebbili KK, Rathod R, Kotak B, Dhanaki G, Shah S.
    Drugs Real World Outcomes; 2024 Jun 14; 11(2):309-316. PubMed ID: 38581564
    [Abstract] [Full Text] [Related]

  • 10. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.
    Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, Shamim S, Islam M.
    Eur J Gastroenterol Hepatol; 2014 Jun 14; 26(6):630-9. PubMed ID: 24722560
    [Abstract] [Full Text] [Related]

  • 11. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J.
    Arq Gastroenterol; 2013 Jun 14; 50(4):304-9. PubMed ID: 24474234
    [Abstract] [Full Text] [Related]

  • 12. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.
    J Clin Gastroenterol; 2012 Mar 14; 46(3):220-7. PubMed ID: 22157240
    [Abstract] [Full Text] [Related]

  • 13. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG.
    J Gastroenterol Hepatol; 2014 Jan 14; 29(1):52-9. PubMed ID: 23829297
    [Abstract] [Full Text] [Related]

  • 14. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome.
    Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P.
    Dig Liver Dis; 2015 Feb 14; 47(2):119-24. PubMed ID: 25488056
    [Abstract] [Full Text] [Related]

  • 15. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.
    Sisson G, Ayis S, Sherwood RA, Bjarnason I.
    Aliment Pharmacol Ther; 2014 Jul 14; 40(1):51-62. PubMed ID: 24815298
    [Abstract] [Full Text] [Related]

  • 16. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial.
    Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE.
    Scand J Gastroenterol; 2013 Oct 14; 48(10):1127-35. PubMed ID: 23957590
    [Abstract] [Full Text] [Related]

  • 17. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome.
    Ducrotté P, Sawant P, Jayanthi V.
    World J Gastroenterol; 2012 Aug 14; 18(30):4012-8. PubMed ID: 22912552
    [Abstract] [Full Text] [Related]

  • 18. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome.
    Stevenson C, Blaauw R, Fredericks E, Visser J, Roux S.
    Nutrition; 2014 Oct 14; 30(10):1151-7. PubMed ID: 25194614
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating.
    Jafari E, Vahedi H, Merat S, Momtahen S, Riahi A.
    Arch Iran Med; 2014 Jul 14; 17(7):466-70. PubMed ID: 24979556
    [Abstract] [Full Text] [Related]

  • 20. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.
    Lorenzo-Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J.
    World J Gastroenterol; 2014 Jul 14; 20(26):8709-16. PubMed ID: 25024629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.